icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
(HCV-TARGET) - Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study
 
 
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
 
N Terrault, S Zeuzem, AM Di Bisceglie, JK Lim, PJ Pockros, LM Frazier, A Kuo, AS Lok, ML Shiffman, Z Ben Ari, T Stewart, MS Sulkowski, MW Fried, and DR Nelson for the HCV-TARGET Study Group
 
from Jules: of note, the authors report PPI use was associated with higher rate of failure; they also report high SVR/success with 8 weeks therapy, equal to 12 weeks:

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif